The Parenteral administration route is the most effective and common form of delivery for active drug substances with poor bio-availability and the drugs with a narrow therapeutic index. Though parenteral administration of drug is often critical and associated with problems such as limited number of acceptable excipients, stringent requirements of aseptic production process, safety issues and patient non-compliance. Still this route maintains its value due to special advantages like quicker onset of action in case of emergency, target the drug quickly to desired site of action, prevention of first pass metabolism etc. The Atrigel system is a proprietary delivery system that can be used for both parenteral and site-specific drug delivery. It consists of biodegradable polymers dissolved in a biocompatible carrier. When the liquid polymer system is placed in the body using standard needles and syringes, it solidifies upon contact with aqueous body fluids to form a solid implant. The ease of manufacture of the Atrigel system and its relatively pain-free subcutaneous injection into the body provide significant advantages over both solid implants and microparticles. Atrigel technology was licensed to the Atrix Laboratories. Atrigel technology currently used in cancer therapy, periodontal treatment and delivery of protein and peptide drugs. By using this technology we can delivered anaesthetics, antibiotics, vaccines, antipsychotics, hormones and NSAIDS in future. This review article complies the information on the in-situ gel forming system i.e. Atrigel technology designed to provide a more stable, ready-to-use formulation to provide drug release in sustained manner.
Loading....